Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Nirmatrelvir+ritonavir/tozinameran

Vaccine failure and rebound effect in the form of SARS-CoV-2 Omicron variant infection relapse: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Marchetti G, et al. Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19. Clinical Microbiology and Infection 29 : 660-662, No. 5, May 2023. Available from: URL: http://doi.org/10.1016/j.cmi.2023.01.016 Marchetti G, et al. Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19. Clinical Microbiology and Infection 29 : 660-662, No. 5, May 2023. Available from: URL: http://​doi.​org/​10.​1016/​j.​cmi.​2023.​01.​016
Metadaten
Titel
Nirmatrelvir+ritonavir/tozinameran
Vaccine failure and rebound effect in the form of SARS-CoV-2 Omicron variant infection relapse: case report
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41578-2

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Tofacitinib

Case report

Heparin

Case report

Antineoplastics